Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-21: Form 8-K; Period of report 2020-12-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2020-11-09: Form 8-K; Period of report 2020-11-09; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
- 2020-09-22: Form 8-K; Period of report 2020-09-22; Description 8.01 Other Events; Details 8.01.
- 2020-08-10: Form 8-K; Period of report 2020-08-10; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-21 | 8-K | 2020-12-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 15, 2020, the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”) appointed Mr. J. David Enloe, Jr. to succeed Gerri Henwood as the Company’s President and Chief Executive Officer. | d19705d8k.htm |
| 2020-11-09 | 8-K | 2020-11-09 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On November 9, 2020, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2020. 8.01 On November 9, 2020, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | reph-8k_20201109.htm |
| 2020-09-22 | 8-K | 2020-09-22 | 8.01 Other Events | 8.01 On September 22, 2020, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d51321d8k.htm |
| 2020-08-10 | 8-K | 2020-08-10 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On August 10, 2020, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2020. 7.01 On August 10, 2020, the Company released a slide presentation, detailing the effect of COVID-19 on national prescription trends, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. 8.01 On August 10, 2020, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference. | d21450d8k.htm |
| 2020-07-29 | 8-K | 2020-07-29 | 8.01 Other Events | 8.01 On July 29, 2020, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d70398d8k.htm |
| 2020-05-15 | 8-K | 2020-05-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure in Item 1.01 and Exhibit 10.1 of this report are incorporated herein by reference. | d900736d8k.htm |
| 2020-05-12 | 8-K | 2020-05-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 11, 2020, Arnaud Ajdler, a member of the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”), notified the Company of his intention to resign from the Board effective May 11, 2020 in order to focus on other commitments and responsibilities. | d918715d8k.htm |
| 2020-05-11 | 8-K | 2020-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2020, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2020. | d917090d8k.htm |
| 2020-03-10 | 8-K | 2020-03-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 6, 2020, Alfred Altomari, a member of the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”), notified the Company of his intention to step down from his position as a member of the Board and as a member of the Audit Committee and Compensation Committee of the Board effective March 6, 2020. | d879091d8k.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2020, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2019. | d795443d8k.htm |
| 2020-01-10 | 8-K | 2020-01-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 6, 2020, Karen Flynn, a member of the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”), notified the Company of her intention to resign from the Board effective January 8, 2020. | d852520d8k.htm |